Johanna Mäenpää

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 406 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I. Ray-Coquard, Alexandra Léary, Sandro Pignata et al. · Annals of Oncology · 2023 · 339 citations · Full text

Medicine, Oncology, Pharmacology +15

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 246 citations

Medicine, Gynecology, Oncology +16

Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland

Tuuli Soini, Ritva Hurskainen, Seija Grénman et al. · Obstetrics and Gynecology · 2014 · 193 citations

Medicine, Gynecology, Oncology +14